Survival analyses were further performed among subgroups divided based on combining HER2 heterogeneity and clinicopathological factors including gender, age, Lauren classification, differentiation, tumor location, number of metastatic sites and radical resection. The gene discussed is ERBB2; the disease is neoplasm.